Fludarabine therapy in Waldenström's macroglobulinemia patients treated previously with 2-chlorodeoxyadenosine.

Abstract:

:Six patients with Waldenström's macroglobulinemia (WM) resistant to previous 2-chlorodeoxyadenosine (2-CdA) therapy were treated with fludarabine. Both initial and subsequent therapy was administered according to the most widely used protocols. The median number of 2-CdA cycles given to the patients was 3.7 (range 2-5), while fludarabine was 1.7 (range 1-2). As a result partial remission was achieved in two patients and stabilization of the disease in the remaining four in spite of the inadequate response or progressive disease after 2-CdA therapy. Median monoclonal IgM concentration fell from 29.4 (range 11.6-37.1) to 16.4 g/l (range 3.8-29.1). At the same time hemoglobin concentration increased from median 114 (range 89-129) to 122 g/l (range 97-133). Side effects consisted of neutropenia (three patients) and thrombocytopenia (two patients). Two patients are alive with progression of the disease noted after 12 and 21 months of observation. One patient died as the result of cardiac disease, two others died of infection 5 and 16 months after cessation of therapy in the course of disease progression. The remaining patient was lost to follow-up after 10 months of observation with continuous stabilization. Our observations suggest that in WM patients resistant to 2-CdA, stabilization of the disease or even remission can be obtained with fludarabine.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Lewandowski K,Halaburda K,Hellmann A

doi

10.1080/10428190290006161

keywords:

subject

Has Abstract

pub_date

2002-02-01 00:00:00

pages

361-3

issue

2

eissn

1042-8194

issn

1029-2403

journal_volume

43

pub_type

杂志文章
  • Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL).

    abstract::Ibrutinib is a first-in-class small molecule inhibitor that has shown remarkable efficacy in the treatment of CLL. Current guidelines recommend lifelong administration at a fixed daily dose of 420 mg. Data from real-world studies indicate up to 17.5% of patients discontinue ibrutinib due to toxicity. Hypothetically, j...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2018.1554862

    authors: Akhtar OS,Attwood K,Lund I,Hare R,Hernandez-Ilizaliturri FJ,Torka P

    更新日期:2019-07-01 00:00:00

  • Study of specific genetic and epigenetic variables in multiple myeloma.

    abstract::Few studies have examined the association between methylenetetrahydrofolate reductase (MTHFR) SNPs, epigenetic changes, and multiple myeloma (MM). We wished to determine genotype distributions for MTHFR 1298AC SNP in cases of MM and healthy controls and to examine whether there is any correlation between the methylati...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2010.528095

    authors: Hatzimichael E,Dasoula A,Benetatos L,Syed N,Dranitsaris G,Crook T,Bourantas K

    更新日期:2010-12-01 00:00:00

  • Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.

    abstract::Inhibiting the activity of Bruton tyrosine kinase (BTK) prevents the activation of the B-cell receptor (BCR) signaling pathway, which in turn prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. Acalabrutinib is an orally available, highly selective, next-generation inhibitor of...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1864352

    authors: Ghia P,Dlugosz-Danecka M,Scarfò L,Jurczak W

    更新日期:2021-01-11 00:00:00

  • Involvement of HLA Antigens, Interleukin 2 Receptor and B-Cell Growth Factor in Interferon Action in Hairy Cell Leukemia.

    abstract::Little is known about the mechanism(s) by which alpha-interferon (aIFN), when used as a biotherapeutic agent, suppresses the malignant cells and restores the normal phenotype of cells in patients with hairy cell leukemia (HCL). In previous studies using scanning electron microscopy (SEM) we found that alFN induced uni...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199009053529

    authors: Gamliel H,Gurfel D,Wu SH,Salzberg S,Golomb HM

    更新日期:1990-01-01 00:00:00

  • Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia.

    abstract::Ibrutinib and idelalisib are kinase inhibitors that have revolutionized the treatment of chronic lymphocytic leukemia (CLL). Capable of inducing durable remissions, these agents also modulate the immune system. Both ibrutinib and idelalisib abrogate the tumor-supporting microenvironment by disrupting cell-cell interac...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2018.1457147

    authors: Pleyer C,Wiestner A,Sun C

    更新日期:2018-12-01 00:00:00

  • The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma.

    abstract::Adult T-cell leukemia/lymphoma (ATL) is frequently a very aggressive malignancy with a poor survival despite aggressive multiagent chemotherapy. The combination of the antiretroviral drug zidovudine (AZT) and interferon alpha (IFNalpha) has been reported to induce remissions in patients with ATL. The purpose of this s...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.3109/10428190109057927

    authors: White JD,Wharfe G,Stewart DM,Maher VE,Eicher D,Herring B,Derby M,Jackson-Booth PG,Marshall M,Lucy D,Jain A,Cranston B,Hanchard B,Lee CC,Top LE,Fleisher TA,Nelson DL,Waldmann TA

    更新日期:2001-01-01 00:00:00

  • Selinexor for advanced hematologic malignancies.

    abstract::Recent measures to classify novel molecular targets with therapeutic potential across multiple hematologic tumors have identified the eukaryotic nuclear exporter, exportin 1 (XPO1), as a promising candidate. Molecular agents termed 'Selective Inhibitors of Nuclear Export' (SINEs) have been developed to selectively inh...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1775210

    authors: Walker JS,Garzon R,Lapalombella R

    更新日期:2020-10-01 00:00:00

  • Candidate gene association studies and risk of chronic lymphocytic leukemia: a systematic review and meta-analysis.

    abstract::To evaluate the contribution of association studies of candidate polymorphisms to inherited predisposition to chronic lymphocytic leukemia (CLL), we conducted a systematic review and meta-analysis of published case-control studies. We identified 36 studies which reported on polymorphic variation in 19 genes and CLL ri...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,meta分析,评审

    doi:10.3109/10428194.2013.800197

    authors: Sava GP,Speedy HE,Houlston RS

    更新日期:2014-01-01 00:00:00

  • Regulation of alloresponses after bone marrow transplantation using donor T cells expressing a thymidine kinase suicide gene.

    abstract::Donor T cells have a critical role in promoting engraftment after allogeneic bone marrow transplantation (BMT), but also cause graft versus host disease (GVHD). Ex vivo T cell depletion has been an effective strategy to reduce GVHD but has been associated with impaired alloengraftment and host immunity. Using an MHC-m...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819021000016041

    authors: Drobyski WR,Gendelman M

    更新日期:2002-10-01 00:00:00

  • Stepdown single agent antibiotic therapy for the management of the high risk neutropenic adult with hematologic malignancies.

    abstract::The standard of therapy for the high risk adult neutropenic host being treated with broad spectrum antibiotics for fever has been to continue intravenous antibiotics until neutropenia resolves. We performed a small, limited pilot study to determine if it is safe to switch these patients to oral monotherapy with ciprof...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.3109/10428199609054816

    authors: Horowitz HW,Holmgren D,Seiter K

    更新日期:1996-09-01 00:00:00

  • Expression of CCR4 in adult T-cell leukemia.

    abstract::Adult T-cell leukemia (ATL) is a malignancy of mature T cells that is etiologically associated with human T-cell leukemia virus type 1 (HTLV-1). The frequent manifestation of ATL is infiltration of leukemic cells into various organs. Besides certain cell adhesion molecules and matrix metalloproteineses, chemokine rece...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190400007607

    authors: Yoshie O

    更新日期:2005-02-01 00:00:00

  • Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia.

    abstract::The objective of this work was to determine the safety and efficacy of gemtuzumab ozogamicin in patients with poor prognosis acute myeloid leukemia (AML). Patients with the following diagnoses/characteristics were treated with 1-3 infusions of gemtuzumab ozogamicin at a dose of 9 mg/m2: (1) relapse of AML < or = 6 mon...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.1080/1042819021000016078

    authors: Roboz GJ,Knovich MA,Bayer RL,Schuster MW,Seiter K,Powell BL,Woodruff RD,Silver RT,Frankel AE,Feldman EJ

    更新日期:2002-10-01 00:00:00

  • Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia.

    abstract::Myelofibrosis with myeloid metaplasia (MMM) is a clonal stem cell disorder that is characterized by florid bone marrow stromal reaction including collagen fibrosis, osteosclerosis, and angiogenesis. Almost all patients with MMM display increased bone marrow microvessel density (MVD) and the extent is among the highest...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190400003267

    authors: Arora B,Mesa R,Tefferi A

    更新日期:2004-12-01 00:00:00

  • Quantitative monitoring of BCR--ABL transcript--suggestion of a simplified approach considering inaccuracy of measurement and calibration.

    abstract::According to standard-protocols, real time quantitative RT-PCR (RQ-PCR) for quantification of BCR-ABL fusion transcripts in CML patients is performed with the construction of a standard curve for each run, each sample is analyzed at least in duplicate and 10-40 ml peripheral blood are processed. This approach is appro...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190310001625845

    authors: Röthlisberger B,Herklotz R,Hergersberg M,Stricker C,Bargetzi M,Huber AR

    更新日期:2004-06-01 00:00:00

  • Parvovirus-B19 infection preceding acute myeloid leukemia with orbital granulocytic sarcoma.

    abstract::We report here an unusual presentation of acute nonlymphoblastic leukemia with ocular granulocytic sarcoma who was firstly diagnosed iron deficiency anemia and acute parvovirus infection induced erythroid hypoplasia. To our knowledge this is the first paper of acute myeloblastic leukemia (AML) with granulocytic sarcom...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819021000016168

    authors: Fisgin T,Yarali N,Duru F,Kara A

    更新日期:2002-10-01 00:00:00

  • Lymphomatous proptosis as a novel feature of mantle cell lymphoma.

    abstract::We describe eight cases of acute proptosis due to mantle cell lymphoma (MCL), among 26 consecutive MCL cases. The median time of onset was 29 months (range 0-102) from diagnosis. Two cases presented initially with orbital masses while five as sudden disease progression after multiple courses of chemotherapy. In each c...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500301058

    authors: Hon C,Chan RT,Ma ES,Shek TW,Yau K,Au WY

    更新日期:2006-01-01 00:00:00

  • Childhood acute lymphoblastic leukemia: is there a tumor suppressor gene in chromosome 12p12.3?

    abstract::Cytogenetic deletions on the short arm of chromosome 12 are common, recurring alterations found in a wide range of hematological neoplasias, including childhood acute lymphoblastic leukemia (ALL), the most frequent pediatric malignancy. This loss of genetic material suggests the presence of a tumor suppressor gene pla...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199909050948

    authors: Aïssani B,Bonan C,Baccichet A,Sinnett D

    更新日期:1999-07-01 00:00:00

  • The role of Aktand RAFTK in beta1 integrin mediated survival of precursor B-acute lymphoblastic leukemia cells.

    abstract::In this study, we report that the related adhesion focal tyrosine kinase RAFTK, is an upstream kinase in beta1 integrin mediated activation of Akt. Stimulation through beta1 integrins by fibronectin reversed apoptosis induced by adriamycin. Inhibitors of phosphatidylinositol 3-kinase (PI3 kinase)/Akt (LY 294002), tyro...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819021000003009

    authors: Sarkar S,Svoboda M,de Beaumont R,Freedman AS

    更新日期:2002-08-01 00:00:00

  • 2'-Deoxycoformycin for hepatosplenic gammadelta T-cell lymphoma.

    abstract::We describe a patient with unusually indolent hepatosplenic gammadelta T cell lymphoma characterised by severe lassitude and high fever. No significant responses were obtained to a range of chemotherapeutic and biological agents. 2'-deoxycoformycin (dCF), however, produced a dramatic and sustained clinical and histolo...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190109099342

    authors: Grigg AP

    更新日期:2001-08-01 00:00:00

  • Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts.

    abstract::The prognostic significance of rare BCR-ABL1 transcripts is uncertain in the tyrosine kinase inhibitor (TKI) era. In this retrospective study, 40 (1.7%) patients with rare BCR-ABL1 transcripts were identified from a cohort of 2331 chronic myeloid leukemia (CML) patients; 4 types of rare transcripts were identified, in...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2019.1607329

    authors: Xue M,Wang Q,Huo L,Wen L,Yang X,Wu Q,Pan J,Cen J,Ruan C,Wu D,Chen S

    更新日期:2019-12-01 00:00:00

  • Secondary hematological malignancies after breast cancer chemotherapy.

    abstract::According to several reports, the 10 year incidence of secondary acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) after systemic chemotherapy is approximately 1.5%. The cumulative risk increases by 0.25--1% for the first 8 years after treatment. We have reported only 6 cases of hematological malignan...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500125705

    authors: Park MJ,Park YH,Ahn HJ,Choi W,Paik KH,Kim JM,Chang YH,Ryoo BY,Yang SH

    更新日期:2005-08-01 00:00:00

  • Cigarette smoking is associated with a small increase in the incidence of non-Hodgkin lymphoma: a meta-analysis of 24 observational studies.

    abstract::Previous studies have evaluated the association between cigarette smoking and incidence of non-Hodgkin lymphoma (NHL) with inconclusive results. Our main objective was to evaluate this relationship using a meta-analysis of observational studies. A literature search was undertaken through October 2011 looking for perti...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,meta分析

    doi:10.3109/10428194.2012.673225

    authors: Castillo JJ,Dalia S

    更新日期:2012-10-01 00:00:00

  • Concomitant primary polycythemia vera and follicle center cell non-Hodgkin lymphoma: a case report and review of the literature.

    abstract::The association of myeloproliferative and lymphoproliferative disorders is well known after cytotoxic drug or radiation exposure, while it is remarkably rare prior to therapy. We report on a patient simultaneously diagnosed as having polycythemia vera and II3A follicle center cell non-Hodgkin lymphoma (grade 1). At th...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/1042819021000016113

    authors: Rizzi R,Liso A,Pannunzio A,Carluccio P,Specchia G,Liso V

    更新日期:2002-11-01 00:00:00

  • Role of vascular endothelial growth factor C in classical Hodgkin lymphoma.

    abstract::We performed three different studies to obtain additional data on the biological and prognostic role of vascular endothelial growth factor C (VEGFC) in classical Hodgkin lymphoma (cHL): (1) serum VEGFC levels were measured by enzyme-linked immunosorbent assay in 80 patients; (2) immunohistochemical VEGFC expression in...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2014.952227

    authors: Rueda A,Olmos D,Vicioso L,Quero C,Gallego E,Pajares-Hachero BI,Mendiola M,Casanova M,Álvarez M,Provencio M,Alba E

    更新日期:2015-05-01 00:00:00

  • Health-related quality of life in survivors of lymphoma: a systematic review and methodological critique.

    abstract::Survival rates for Hodgkin lymphoma and non-Hodgkin lymphoma have improved in recent years. However, these improvements are associated with various late effects, which can compromise health-related quality of life (HRQoL). Improving HRQoL is a significant goal in oncology, and increasingly one of the primary outcomes ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428191003587263

    authors: Arden-Close E,Pacey A,Eiser C

    更新日期:2010-04-01 00:00:00

  • Long non-coding RNA GAS5 polymorphism predicts a poor prognosis of acute myeloid leukemia in Chinese patients via affecting hematopoietic reconstitution.

    abstract::Whether long non-coding RNA (lncRNA) single-nucleotide polymorphisms (SNPs) affect prognosis of acute myeloid leukemia (AML) remains unknown. To search the association between lncRNA SNPs and AML outcomes, thirty tagSNPs in five lncRNAs were genotyped in 313 AML patients. Survival analysis indicated that GAS5 rs558296...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2016.1266626

    authors: Yan H,Zhang DY,Li X,Yuan XQ,Yang YL,Zhu KW,Zeng H,Li XL,Cao S,Zhou HH,Zhang W,Chen XP

    更新日期:2017-08-01 00:00:00

  • The role of T cell costimulation by CD80 in the initiation and maintenance of the immune response to human leukemia.

    abstract::Most human myeloid leukemias express both class I and class II HLA and it has been postulated that leukemia-associated peptides are presented by those molecules. It is possible, however, that leukemia cells escape the immune surveillance by lacking expression of "costimulatory" molecules required for activating the im...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428199909169607

    authors: Matsumoto K,Anasetti C

    更新日期:1999-11-01 00:00:00

  • Idiopathic primary osteo-myelofibrosis: a clinico-pathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognostic impact.

    abstract::A retrospective clinico-pathological study was performed on 208 consecutively recruited patients (94 males, 114 females, median age 67 years) with idiopathic (primary) osteo-/ myelofibrosis (IMF). According to bone marrow histology (cellularity) as well as extent (semiquantitative grading) and quality (reticulin/colla...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199609051762

    authors: Thiele J,Kvasnicka HM,Werden C,Zankovich R,Diehl V,Fischer R

    更新日期:1996-07-01 00:00:00

  • Phase II study of sequential topotecan and etoposide in patients with intermediate grade non-Hodgkin's lymphoma: a National Cancer Institute of Canada Clinical Trials Group study.

    abstract::Preliminary results indicate that inhibitors of the nuclear enzyme topoisomerase (topo) I, such as topotecan, may be active in non-Hodgkin's lymphoma (NHL). Pre-clinical studies have shown sequential administration of a topo I and II inhibitor has supra-additive anti-tumor effects in some model systems, and that great...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.1080/1042819021000002901

    authors: Crump M,Couban S,Meyer R,Rudinskas L,Zanke B,Gluck S,Maksymiuk A,Hoskins P,Matthews S,Eisenhauer E

    更新日期:2002-08-01 00:00:00

  • SOX11 and HIG-2 are cross-regulated and affect growth in mantle cell lymphoma.

    abstract::The transcriptional factor SOX11 is a disease-defining antigen in mantle cell lymphoma (MCL) and absent in most non-malignant tissues. To explore the role of SOX11-related cell signaling, and potentially take benefit from these for targeted therapy, associated networks and proteins need to be defined. In this study, w...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2015.1121257

    authors: Kuci V,Nordström L,Conrotto P,Ek S

    更新日期:2016-08-01 00:00:00